Insulin, insulin-like growth factors and neoplasia

Insulin, insulin-like growth factors and neoplasia Over the past decade, dozens of epidemiological studies and laboratory experiments have provided evidence for relationships between insulin-like growth factor (IGF) physiology and neoplasia. Population studies provide evidence for a modestly increased risk of a subsequent cancer diagnosis in subjects with IGF-I levels at the high end of the broad normal range, as compared to those at the low end of the normal range. At the cellular level, IGF-I receptor signalling has been shown to play an important role in facilitating the transforming action of a variety of oncogenes. Reducing receptor function with anti-receptor antibodies or specific tyrosine kinase inhibitors reduces the proliferation of many cancers in vitro and in vivo. At present, clinical relevance of the relationship between circulating IGF-I level and cancer risk is limited, but in terms of experimental therapeutics, many clinical trials have been initiated to investigate the possibility that the paradigm of hormonal treatment of cancer may be extended from targeting gonadal steroids to targeting the growth hormone–IGF-I axis. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Best Practice & Research Clinical Endocrinology & Metabolism Elsevier

Insulin, insulin-like growth factors and neoplasia

Loading next page...
 
/lp/elsevier/insulin-insulin-like-growth-factors-and-neoplasia-B1P0CQLwVz
Publisher
Elsevier
Copyright
Copyright © 2008 Elsevier Ltd
ISSN
1521-690X
eISSN
1532-1908
D.O.I.
10.1016/j.beem.2008.08.004
Publisher site
See Article on Publisher Site

Abstract

Over the past decade, dozens of epidemiological studies and laboratory experiments have provided evidence for relationships between insulin-like growth factor (IGF) physiology and neoplasia. Population studies provide evidence for a modestly increased risk of a subsequent cancer diagnosis in subjects with IGF-I levels at the high end of the broad normal range, as compared to those at the low end of the normal range. At the cellular level, IGF-I receptor signalling has been shown to play an important role in facilitating the transforming action of a variety of oncogenes. Reducing receptor function with anti-receptor antibodies or specific tyrosine kinase inhibitors reduces the proliferation of many cancers in vitro and in vivo. At present, clinical relevance of the relationship between circulating IGF-I level and cancer risk is limited, but in terms of experimental therapeutics, many clinical trials have been initiated to investigate the possibility that the paradigm of hormonal treatment of cancer may be extended from targeting gonadal steroids to targeting the growth hormone–IGF-I axis.

Journal

Best Practice & Research Clinical Endocrinology & MetabolismElsevier

Published: Aug 1, 2008

References

  • Insulin-like growth factors and neoplasia
    Pollak, M.N.; Schernhammer, E.S.; Hankinson, S.E.
  • PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2
    Levitt, R.J.; Georgescu, M.M.; Pollak, M.
  • IGF-I mediated survival pathways in normal and malignant cells
    Kurmasheva, R.T.; Houghton, P.J.
  • Are findings from studies of obesity and prostate cancer really in conflict?
    Freedland, S.J.; Giovannucci, E.; Platz, E.A.
  • In vitro metformin anti-neoplastic activity in epithelial ovarian cancer
    Gotlieb, W.H.; Saumet, J.; Beauchamp, M.C.
  • Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
    Zakikhani, M.; Dowling, R.; Fantus, I.G.
  • Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751,871 in patients with sarcoma
    Olmos, D.; Okuno, S.; Schuetze, S.M.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off